Epigenetic priming with decitabine followed by low- dose idarubicin /cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Ye, Xing-nong; Zhou, Xin-ping; Wei, Ju-ying; Xu, Gai-xiang; Li, Ying; Mao, Li-ping; Huang, Jian; Ren, Yan-Ling; Mei, Chen; Wang, Jing-han; Lou, Yin-jun; Ma, Li-ya; Yu, Wen-juan; Ye, Li; Xie, Li-li; Luo, Yin-wan; Hu, Chao; Niu, Lin-mei; Dou, Min-hua; Jin, Jie; Tong, Hong-yan

期刊名称Leukemia & Lymphoma
作者Ye, Xing-nong; Zhou, Xin-ping; Wei, Ju-ying; Xu, Gai-xiang; Li, Ying; Mao, Li-ping; Huang, Jian; Ren, Yan-Ling; Mei, Chen; Wang, Jing-han; Lou, Yin-jun; Ma, Li-ya; Yu, Wen-juan; Ye, Li; Xie, Li-li; Luo, Yin-wan; Hu, Chao; Niu, Lin-mei; Dou, Min-hua; Jin, Jie; Tong, Hong-yan
印刷ISSN1042-8194
电子ISSN1029-2403
文件大小857.34KB
发表时间2015-09-15
DOI10.3109/10428194.2015.1091931
页码1-24

发现好书期刊，享受阅读乐趣

Epigenetic priming with decitabine followed by low- dose idarubicin /cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms